Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$307.42 USD

307.42
2,447,408

+1.57 (0.51%)

Updated Jun 3, 2024 04:00 PM ET

After-Market: $307.41 -0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva

Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA

by Zacks Equity Research

Amgen Inc. (AMGN) announced that the FDA has accepted its supplemental Biologics License Application (sBLA) to expand the label of its key drug, Xgeva.

    AbbVie (ABBV) Stock Hits 52-Week High: More Room to Run?

    by Zacks Equity Research

    AbbVie Inc. (ABBV) shares hit a 52-week high of $71.12 on Friday before eventually closing at $71.05.

      Nektar (NKTR) Stock Rallied Almost 50% This Year: Here's Why

      by Zacks Equity Research

      Shares of Nektar Therapeutics (NKTR) are up almost 48% this year so far, outperforming the Zacks classified Medical-Drugs industry's registered increase of 3.6% during this period.

        Is Amgen (AMGN) a Great Stock for Value Investors?

        by Zacks Equity Research

        Let's see if Amgen Inc. (AMGN) stock is a good choice for value-oriented investors right now from multiple angles.

          Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx

          by Zacks Equity Research

          Novartis AG (NVS) announced positive data on arthritis drug Cosentyx from two phase III studies.

            Why Is ImmunoGen (IMGN) Stock Up 131% This Year?

            by Zacks Equity Research

            Shares of ImmunoGen, Inc. (IMGN) are massively up 130.9% this year so far, outperforming the the Zacks classified Medical-Drugs industry's registered 3.6% increase during this period.

              Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar

              by Zacks Equity Research

              Coherus Biosciences, Inc. (CHRS) shares declined nearly 24% in yesterday's trading as it announced that it has received a complete response letter (CRL) from the FDA for its biosimilar version of Amgen Inc's (AMGN) blockbuster drug, Neulasta.

                Merck Stalls Enrolment in Two Myeloma Studies of Keytruda

                by Zacks Equity Research

                Merck & Co., Inc. (MRK) announced that it is pausing two late-stage studies evaluating its anti-PD-1 therapy, Keytruda, as a combination therapy for the treatment of multiple melanoma, a form of blood cancer.

                  Amgen's Multiple Myeloma Drug Receives NICE Recommendation

                  by Zacks Equity Research

                  Amgen Inc. (AMGN) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma.

                    Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies

                    by Zacks Equity Research

                    Sanofi (SNY) and partner Regeneron Pharmaceuticals, Inc. (REGN) announced that their PCSK9 inhibitor, Praluent significantly reduced bad cholesterol in two late-stage studies.

                      AbbVie (ABBV) Announced Positive Phase III RA Candidate Data

                      by Zacks Equity Research

                      AbbVie Inc. (ABBV) announced positive top-line results from a phase III study on rheumatoid arthritis candidate, upadacitinib (ABT-494).

                        Teva Migraine Candidate Succeeds in Second Phase III Study

                        by Zacks Equity Research

                        Teva announced that its experimental migraine prevention candidate, fremanezumab, met all the primary and secondary endpoints in a second late-stage study.

                          Allergan to Buy Keller Funnel, Boost Plastic Surgery Unit

                          by Zacks Equity Research

                          Allergan plc (AGN) announced a deal to acquire privately held medical device company Keller Medical, Inc, which makes Keller Funnel, for an undisclosed amount.

                            Merck's Cancer Drug Keytruda Positive in Clinical Studies

                            by Zacks Equity Research

                            Merck & Co., Inc. (MRK) announced positive data from a phase III study KEYNOTE-024, evaluating its anti-PD-1 therapy, Keytruda (pembrolizumab) for first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC).

                              Amgen Files for Repatha in the U.S., EU for Expanded Use

                              by Zacks Equity Research

                              Biotech major, Amgen, Inc. (AMGN) announced that it submitted regulatory applications for its PCSK9 inhibitor, Repatha in both the U.S. and EU.

                                Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs

                                by Zacks Equity Research

                                Amgen, Inc. (AMGN) presented encouraging results from a phase III study, evaluating its marketed drug Xgeva (denosumab) for an expanded indication at the American Society of Clinical Oncology.

                                  Amgen (AMGN) Down 4.5% Since Earnings Report: Can It Rebound?

                                  by Zacks Equity Research

                                  Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                    Pfizer's Epogen Biosimilar Gets Positive FDA Committee Vote

                                    by Zacks Equity Research

                                    Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.

                                      The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

                                      by Zacks Equity Research

                                      The Zacks Analyst Blog Highlights: Regeneron, Amgen and Celgene

                                        Radius Health Osteoporosis Drug Positive in Phase III Study

                                        by Zacks Equity Research

                                        Radius Health, Inc. (RDUS) announced positive data from the ACTIVExtend study on Tymlos demonstrating significant reduction (84%) in the incidence of new vertebral fractures compared to placebo when dosed daily for 43 months.

                                          Merck's (MRK) Keytruda Gets FDA Nod for Solid Tumor Cancers

                                          by Zacks Equity Research

                                          Merck & Co., Inc. (MRK) announced that Keytruda, has received accelerated approval for the treatment of microsatellite instability-high (MSI-H) or mismatch repair deficient solid tumors .

                                            Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

                                            by Zacks Equity Research

                                            Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

                                              Amgen Evenity Approval Derailed on Cardiovascular Side Effect

                                              by Zacks Equity Research

                                              A late-stage study at Amgen, Inc. (AMGN) showed that its pipeline candidate Evenity/romosozumab led to a statistically significant superior fracture risk reduction.

                                                Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

                                                by Zacks Equity Research

                                                Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

                                                  Merck's (MRK) Keytruda Gets FDA Nod for Two New Indications

                                                  by Zacks Equity Research

                                                  Merck & Co., Inc. (MRK) announced that the FDA has approved two new indications for Keytruda (pembrolizumab), the company's anti-PD-1 therapy.